NASDAQ:RTTRRitter Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.45 -5.95 (-93.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.45Now: $0.45▼$0.4550-Day Range$0.25MA: $0.40▼$0.7252-Week Range$0.15Now: $0.45▼$1.27VolumeN/AAverage Volume14.23 million shsMarket Capitalization$20.68 millionP/E RatioN/ADividend YieldN/ABeta-0.43 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Ritter Pharmaceuticals. Previous Next 2.7 Community Rank Outperform VotesRitter Pharmaceuticals has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRitter Pharmaceuticals has received 256 “underperform” votes. (Add your “underperform” vote.)Community SentimentRitter Pharmaceuticals has received 53.87% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote “Outperform” if you believe RTTR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRitter Pharmaceuticals does not currently pay a dividend.Dividend GrowthRitter Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ritter Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,125.00 in company stock.Percentage Held by InsidersOnly 15.40% of the stock of Ritter Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.84% of the stock of Ritter Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Ritter Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ritter Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRitter Pharmaceuticals has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RTTR Previous Symbol CUSIPN/A CIK1460702 Webwww.ritterpharmaceuticals.com Phone310-203-1000Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book4.48Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,130,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-162.05%Miscellaneous Employees7 Outstanding Shares46,153,000Market Cap$20.68 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:RTTR Rates by TradingView Receive RTTR News and Ratings via Email Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions How has Ritter Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Ritter Pharmaceuticals' stock was trading at $0.2680 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RTTR shares have increased by 67.2% and is now trading at $0.4480. View which stocks have been most impacted by Coronavirus. When is Ritter Pharmaceuticals' next earnings date? Ritter Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Ritter Pharmaceuticals. How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. View Ritter Pharmaceuticals' earnings history. When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work? Ritter Pharmaceuticals's stock reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. Has Ritter Pharmaceuticals been receiving favorable news coverage? News articles about RTTR stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRitter Pharmaceuticals. Who are some of Ritter Pharmaceuticals' key competitors? Some companies that are related to Ritter Pharmaceuticals include ContraFect (CFRX), Synlogic (SYBX), Leap Therapeutics (LPTX), Otonomy (OTIC), Milestone Pharmaceuticals (MIST), Proteostasis Therapeutics (PTI), resTORbio (TORC), Oramed Pharmaceuticals (ORMP), Adamas Pharmaceuticals (ADMS), SCYNEXIS (SCYX), CTI BioPharma (CTIC), Stealth BioTherapeutics (MITO), Enlivex Therapeutics (ENLV), Alpine Immune Sciences (ALPN) and CannTrust (CNTTF). View all competitors. What other stocks do shareholders of Ritter Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Apache (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and Primo Water (PRMW). Who are Ritter Pharmaceuticals' key executives? Ritter Pharmaceuticals' management team includes the following people: Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)Mr. Michael D. Step, Consultant & Director (Age 59)Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)Ms. Ellen F. Mochizuki, Consultant (Age 52) When did Ritter Pharmaceuticals IPO? (RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager. What is Ritter Pharmaceuticals' stock symbol? Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR." How do I buy shares of Ritter Pharmaceuticals? Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ritter Pharmaceuticals' stock price today? One share of RTTR stock can currently be purchased for approximately $0.45. How big of a company is Ritter Pharmaceuticals? Ritter Pharmaceuticals has a market capitalization of $20.68 million. Ritter Pharmaceuticals employs 7 workers across the globe. What is Ritter Pharmaceuticals' official website? The official website for Ritter Pharmaceuticals is www.ritterpharmaceuticals.com. How can I contact Ritter Pharmaceuticals? Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
